The existing methods and devices of degassing fuel liquid, special liquids in weightlessness conditions are expensive and economically not advantageous, since degassing is achieved by a complex, not effective method on the technically bulky devices. The developed methods of degassing fuel liquid and special liquids in the power supply and life-support systems of automatic spacecraft using the controlled vibration or the specially created temperature gradient in the liquid are simple on its construction, economically highly effective and productive. The developed methods permit to produce the unique gasfilled materials with uniform distribution of fine dispersed gas phase using the application of electric field and controlled vibration or electric field and inertial forces in the conditions of space flight. The developed method of processing in weightlessness of antitumorigenic medicines with uniform distribution of spherical drops of cytostatic, which permit during implanting of medicine inside of body parts of patient,which feed by blood tumor, with calculated dose of cytostatic to act directly on tumor cells at the moment of their mitosis.
In the book the existing at present time scientific concepts about the cholesteric liquid crystals are considered: the structure of the molecules of the substances, which form them, the textures, which they form, the molecular structures, from which they consist, the unique physical properties, which they possess. On the basis of the property of cholesteric liquid crystals under the change of the temperature to change their color were used cholesteric liquidcrystal films and were developed: the device for diagnostics of breast cancer, which are usual and comfortable for the women under conducting of diagnostics that permits to obtain the qualitative, contrasting with the high accuracy colored image of benign or malignant tumor, the music color device, which permits to "revive" by the different colors image on the panel in accordance with the frequency spectrum of the signal, which is coming from the electronic-music device, the indicator of sorption processes, which ensures the indication of sorption on the surface of mineral, by simple, safe, express and cheap method.
High Quality Content by WIKIPEDIA articles! Radical surgery refers to the removal of blood supply, lymph nodes and sometimes adjacent structures of a diseased organ or tumor during surgery. In surgical oncology, radical surgery (or dissection) typically describes the removal of a tumor or mass and ancillary lymph nodes that may drain the mass for diagnostic and/or treatment purposes, as in radical mastectomy. Blood is a specialized bodily fluid that delivers necessary substances to the body's cells such as nutrients and oxygen and transports waste products away from those same cells. In vertebrates, it is composed of blood cells suspended in a liquid called blood plasma. Plasma, which comprises 55% of blood fluid, is mostly water (90% by volume), and contains dissolved proteins, glucose, mineral ions, hormones, carbon dioxide (plasma being the main medium for excretory product transportation), platelets and blood cells themselves.
In the book is represented the computer model of the behavior of gas bubble both in the Earth's conditions and in the conditions of the acceleration of gravity change. The computer model of the behavior of gas bubbles in the vibrating liquid with a change of the acceleration of the gravity is shown. The developed computer models have been proved experimentally during the process of the conducted tests on the board of the flying laboratory (FL) IL-76 K and showed the possibility of their practical use for the simulation of the behavior of real gas bubbles in the life-support systems and power supply technological processes of automatic spacecraft, in the conditions of real space flight. The computer system of optimal interpolation prognosis illustrates, which permits to create the medico-mathematical model of tumor, numerically reflecting all laws governing the flow of tumor process after the conducted treatment, to plan the optimum tactics of postoperative control, of the selection of the periods of test survey and regimes of the preventive treatment of oncological patients, to determine the effectiveness of the used methods of treatment of the oncological patients.
The complex landscape of breast cancer requires distinct strategies for the management of various molecular subtypes of this disease. Rapid advances in the field of molecular biology have been bewildering for those involved in its study and management. "Molecular Pathology of Breast Cancer" aims to close this knowledge gap by discussing comprehensively the evolution, biological basis and clinical applications with a focus on the "what, when, and how" of the most significant molecular markers known to date. These markers are evaluated in the context of genomic, transcriptomic and proteomic profiles, which is integral to the practice of precision medicine.The application of next generation sequencing (NGS) has provided new insights in the regulation of genomic and transcriptomic structure and function. Alterations in DNA such as mutations and single nucleotide polymorphisms (SNPs) have been correlated with outcomes and provide for novel therapeutic approaches. These NGS analyses have also revealed the extensive contributions of epigenetic mechanisms such as histone modifications, non-coding RNA and alternative splicing. All of these changes together contribute to alterations in proteome. Newer assays that allow greater stability and analytical consistency are emerging. These alterations in tumor profiles can be also now detected by imaging techniques.The heterogeneity of both tumor and tumor microenvironment, an inevitable reality, is discussed in detail with particular focus on cancer stem cells and immune signaling. A chapter is dedicated to the emerging technology of "liquid biopsy", which opens a novel approach for "continuous" monitoring of cancer that might be superior to conventional diagnostics,"Molecular Pathology of Breast Cancer" provides a quick and easy, not to mention essential, tour for clinicians, pathologists and scientists who are seeking to understand the integration of molecular biology into the diagnosis, prognosis and management of breast cancer.
This volume, with chapters written by experts in the field of cancerous tumors, details the key factors associated with liquid biopsies in solid tumors: blood-based diagnostics, circulating tumor cells, enumeration and molecular analysis (association with breast cancer), epithelialmesenchymal transition, detection and monitoring, circulating-free tumor DNA, CTCs and ctDNA, and the exosome. The field of blood-based diagnostics is rapidly evolving demonstrating the possibility of real-time molecular analysis of cancer cells and their phenotype and genotype.Circulating Tumor Cell (CTCs) have demonstrated prognostic and predictive value in advanced cancer and represents a source of tumor cells for transcriptome and genomic analysis. Most recently, the detection of genomic abnormalities in the peripheral blood by sensitive and selective PCR methods (liquid biopsy) opened to the option of a comprehensive blood-based tumor analysis. Similar information can be obtained by analysis of exosome, a natural packaging and messaging system being explored in advanced malignancies. The final frontier is the evaluation of immune cells determinant of innate and adaptive immunity.
Violacein and deoxyviolacein are promising therapeutics against pathogenic bacteria and viruses as well as tumor cells. In the present work, systems-wide metabolic engineering was applied to Escherichia coli for heterologous production of these high-value products. First, a high performance liquid chromatography method for accurate separation and quantification of violacein and deoxyviolacein was developed. Afterwards, a basic producer, E. coli dVio-1, that expressed the vioABCE cluster from Chromobacterium violaceum under control of the araBAD promoter and induction by L-arabinose, was constructed. Targeted intracellular metabolite analysis then identified bottlenecks in pathways that supply tryptophan, the major product building block of the natural products of interest. This was used for systems-wide engineering of serine, chorismate and tryptophan biosynthesis and the non-oxidative pentose-phosphate pathway, followed by elimination of L-arabinose catabolism. Transferred to a glycerol-based fed-batch process, E. coli dVio-8 surpassed the gram scale and produced 1.6 g L-1 deoxyviolacein (> 99.5% purity). The created chassis of a high-flux tryptophan pathway was complemented by genomic integration of the vioD gene of Janthinobacterium lividum, which enabled exclusive production of violacein (710 mg L-1 with 99.8% purity). This demonstrates the potential of E. coli as a platform for production of tryptophan based therapeutics.
This text is designed to provide readers with a useful and comprehensive resource and state-of-the-art overview about the new, growing and fast-expanding field of "liquid biopsy" for the management of cancer patients. The liquid biopsy represents an important turning point in oncology since it provides a tool for a serial monitoring of disease. Liquid biopsy is our "hand lens" to follow molecular changes that characterize tumor development and progression. The book provide a unique and valuable resource on the clinical relevance of liquid biopsy as well as on the technical aspects of liquid biopsy analysis. All invited authors are recognized experts in their field. Liquid Biopsy in Cancer Patients: The Hand Lens for Tumor Evolution is targeted to resident and fellows physicians, medical oncologists, molecular biologists and biotechnologists.
This book is a comprehensive guide to the techniques, clinical applications, and benefits of the different forms of liquid biopsy employed in patients with a variety of tumor types, including lung, breast and colorectal cancer. Offering detailed explanations, it discusses the how changes in tumors can be tracked using these cutting-edge technologies, which enable the detection and analysis of diverse circulating biomarkers: tumor cells, tumor DNA, tumor RNA (free or in exosomes), and fluid biomarkers identifiable by means of targeted proteomics. The use of such advanced technologies is enabling us to tackle questions and problems in a way that was not possible just a few years ago. We now have at our disposal an effective means of overcoming the problem of intratumor heterogeneity, which has limited the value of conventional biopsy approaches. As a consequence, oncology practice is about to change radically, toward truly personalized precision medicine. This book provides both clinicians and researchers with a thorough and up-to-date overview of progress in the field.